CCL18 and idiopathic pulmonary fibrosis: Such predominant expression of CCL18 in the lungs and its direct stimulation of collagen production independent of TGF-β suggest this chemokine as a potential independent target in strategies to prevent IPF, with fewer adverse effects than TGF-β-targeting therapies [93,94,95].